Form 4: Axsome Therapeutics CEO Herriot Tabuteau Reports Stock Option and Unit Awards

CEO Herriot Tabuteau reports the acquisition of stock options, restricted stock units (RSUs), and performance stock units (PSUs) in Axsome Therapeutics.

Summary

• Herriot Tabuteau, CEO of Axsome Therapeutics, filed a Form 4 detailing changes in beneficial ownership.
• The report indicates the acquisition of 28,887 employee stock options at an exercise price of $137.75, vesting quarterly over four years, fully vested by February 21, 2029.
• Tabuteau also acquired 28,609 restricted stock units (RSUs), with 25% vesting after one year and the remainder vesting in three equal annual installments, fully vested by February 21, 2029.
• Vested RSU shares will be delivered upon a Change in Control, separation of service, or seven years from the grant date.
• Additionally, 28,609 performance stock units (PSUs) were acquired, vesting upon achievement of certain financial, regulatory, and developmental milestones.
• The reporting person directly owns all the securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The granting of stock options and units is a standard practice and reflects confidence in the company's future performance. The vesting schedules incentivize long-term value creation.

Positives

• The grant of stock options, RSUs, and PSUs aligns the CEO's interests with the long-term performance of Axsome Therapeutics.
• The vesting schedules for the options and units incentivize continued service and achievement of milestones.

Industry Context

Stock-based compensation is a common practice in the pharmaceutical industry to attract and retain top talent and align their interests with shareholder value. The vesting schedules and performance-based units are typical mechanisms to incentivize long-term performance and achievement of key milestones.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the pharmaceutical industry, often benchmarked against peer companies of similar size and stage of development.
• RSUs and PSUs are also common, with vesting schedules and performance metrics tailored to the specific goals and priorities of the company.
• Companies like Biogen, Amgen, and Vertex Pharmaceuticals also utilize similar equity-based compensation strategies for their executives.

Stakeholder Impact

• Shareholders may view the stock-based compensation as a positive sign, aligning management's interests with the company's long-term success.
• Employees may be motivated by the potential for future gains through stock options and units.

Key Dates